Omics Core℠
The First FDA-Cleared Whole Exome Sequencing Platform for Overall Tumor Mutation Burden
GPS Cancer® and Liquid GPS™: For Health Plans and Employers
Brochure
Read more
Precise molecular profiling for informed, personalized cancer treatment strategies
Forward-thinking organizations are covering NantHealth molecular profiling so that individuals with cancer will have access to precise and comprehensive information when they need it most.
Additional Resources
Data from NantHealth’s GPS Cancer platform reveals increased...
Oncotarget Research Paper (April 2018)
GPS Cancer Health Plan / Employer Brochure
Brochure
GPS Cancer Physician Brochure
Brochure
NantHealth Presents Research Demonstrating Real World Evidence of...
NantHealth Announces FDA Marketing Authorization of Omics CoreSM:...
NantHealth® and NantOmics to Present Evidence for Selective...
NantHealth® and NantOmics to Present Data on Tumor...
NantHealth® and Northwest Firefighters Benefits Trust (NWFFT) Join...
NantHealth® and NantOmics to Reveal New Research Demonstrating...
NantHealth® and NantOmics to Reveal New Research at...
NantCell Announces New Celgene Investment
